FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022868259> ?p ?o ?g. }

• W2022868259 endingPage "254S" @default.
• W2022868259 startingPage "249S" @default.
• W2022868259 abstract "Chemotherapy remains the mainstay of treatment for small cell lung cancer (SCLC). For patients with limited-stage disease, the addition of thoracic radiotherapy confers a moderate improvement in local control and a modest survival benefit, but these improvements come at the cost of increased toxic reactions. The optimal method for integrating chemotherapy and thoracic radiotherapy is unresolved. Concurrent and alternating strategies are appealing because they allow uninterrupted delivery of chemotherapy, but they have not been proven to be superior to conventional sequential approaches. Based on limited data, delivery of thoracic radiation early in the treatment course may be preferable to delivery later in the course. There is evidence of a radiation dose-response effect for SCLC, and, in standard regimens, thoracic radiation doses in the range of 50 to 60 Gy are recommended. The use of limited radiation fields (to postchemotherapy tumor volumes) appears reasonable. Results for alternative thoracic radiation fractionation schedules such as accelerated hyperfractionation are promising and worthy of further investigation. The role of prophylactic cranial irradiation (PCI) is controversial and should be individualized. It should be considered for the favorable subgroup of patients with limited-stage disease who achieve a complete response to chemotherapy and thoracic radiotherapy. If given, we recommend a total dose of 30 to 36 Gy in 2-Gy fractions; PCI should not be delivered concomitantly with chemotherapy. Chemotherapy remains the mainstay of treatment for small cell lung cancer (SCLC). For patients with limited-stage disease, the addition of thoracic radiotherapy confers a moderate improvement in local control and a modest survival benefit, but these improvements come at the cost of increased toxic reactions. The optimal method for integrating chemotherapy and thoracic radiotherapy is unresolved. Concurrent and alternating strategies are appealing because they allow uninterrupted delivery of chemotherapy, but they have not been proven to be superior to conventional sequential approaches. Based on limited data, delivery of thoracic radiation early in the treatment course may be preferable to delivery later in the course. There is evidence of a radiation dose-response effect for SCLC, and, in standard regimens, thoracic radiation doses in the range of 50 to 60 Gy are recommended. The use of limited radiation fields (to postchemotherapy tumor volumes) appears reasonable. Results for alternative thoracic radiation fractionation schedules such as accelerated hyperfractionation are promising and worthy of further investigation. The role of prophylactic cranial irradiation (PCI) is controversial and should be individualized. It should be considered for the favorable subgroup of patients with limited-stage disease who achieve a complete response to chemotherapy and thoracic radiotherapy. If given, we recommend a total dose of 30 to 36 Gy in 2-Gy fractions; PCI should not be delivered concomitantly with chemotherapy." @default.
• W2022868259 created "2016-06-24" @default.
• W2022868259 creator A5021503571 @default.
• W2022868259 creator A5064033579 @default.
• W2022868259 date "1995-06-01" @default.
• W2022868259 modified "2023-09-25" @default.
• W2022868259 title "Thoracic and Cranial Radiotherapy for Limited-Stage Small Cell Lung Cancer" @default.
• W2022868259 cites W1480091719 @default.
• W2022868259 cites W1839070320 @default.
• W2022868259 cites W1885320430 @default.
• W2022868259 cites W1895855332 @default.
• W2022868259 cites W1905406155 @default.
• W2022868259 cites W1923792259 @default.
• W2022868259 cites W1973865448 @default.
• W2022868259 cites W1976276185 @default.
• W2022868259 cites W1977154928 @default.
• W2022868259 cites W1986382059 @default.
• W2022868259 cites W1989315499 @default.
• W2022868259 cites W2010947937 @default.
• W2022868259 cites W2018928207 @default.
• W2022868259 cites W2047985326 @default.
• W2022868259 cites W2053048296 @default.
• W2022868259 cites W2056049978 @default.
• W2022868259 cites W2060711937 @default.
• W2022868259 cites W2070645346 @default.
• W2022868259 cites W2073005838 @default.
• W2022868259 cites W2088766047 @default.
• W2022868259 cites W2089016789 @default.
• W2022868259 cites W2098082363 @default.
• W2022868259 cites W2103926757 @default.
• W2022868259 cites W2121624379 @default.
• W2022868259 cites W2243683089 @default.
• W2022868259 cites W2258518953 @default.
• W2022868259 cites W2341745217 @default.
• W2022868259 cites W2405391497 @default.
• W2022868259 cites W2418513986 @default.
• W2022868259 doi "https://doi.org/10.1378/chest.107.6_supplement.249s" @default.
• W2022868259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7781402" @default.
• W2022868259 hasPublicationYear "1995" @default.
• W2022868259 type Work @default.
• W2022868259 sameAs 2022868259 @default.
• W2022868259 citedByCount "6" @default.
• W2022868259 crossrefType "journal-article" @default.
• W2022868259 hasAuthorship W2022868259A5021503571 @default.
• W2022868259 hasAuthorship W2022868259A5064033579 @default.
• W2022868259 hasConcept C126322002 @default.
• W2022868259 hasConcept C126838900 @default.
• W2022868259 hasConcept C141071460 @default.
• W2022868259 hasConcept C143998085 @default.
• W2022868259 hasConcept C146357865 @default.
• W2022868259 hasConcept C151730666 @default.
• W2022868259 hasConcept C155806632 @default.
• W2022868259 hasConcept C2776256026 @default.
• W2022868259 hasConcept C2776694085 @default.
• W2022868259 hasConcept C2779562246 @default.
• W2022868259 hasConcept C2908786992 @default.
• W2022868259 hasConcept C45393284 @default.
• W2022868259 hasConcept C500558357 @default.
• W2022868259 hasConcept C509974204 @default.
• W2022868259 hasConcept C71924100 @default.
• W2022868259 hasConcept C86803240 @default.
• W2022868259 hasConceptScore W2022868259C126322002 @default.
• W2022868259 hasConceptScore W2022868259C126838900 @default.
• W2022868259 hasConceptScore W2022868259C141071460 @default.
• W2022868259 hasConceptScore W2022868259C143998085 @default.
• W2022868259 hasConceptScore W2022868259C146357865 @default.
• W2022868259 hasConceptScore W2022868259C151730666 @default.
• W2022868259 hasConceptScore W2022868259C155806632 @default.
• W2022868259 hasConceptScore W2022868259C2776256026 @default.
• W2022868259 hasConceptScore W2022868259C2776694085 @default.
• W2022868259 hasConceptScore W2022868259C2779562246 @default.
• W2022868259 hasConceptScore W2022868259C2908786992 @default.
• W2022868259 hasConceptScore W2022868259C45393284 @default.
• W2022868259 hasConceptScore W2022868259C500558357 @default.
• W2022868259 hasConceptScore W2022868259C509974204 @default.
• W2022868259 hasConceptScore W2022868259C71924100 @default.
• W2022868259 hasConceptScore W2022868259C86803240 @default.
• W2022868259 hasIssue "6" @default.
• W2022868259 hasLocation W20228682591 @default.
• W2022868259 hasLocation W20228682592 @default.
• W2022868259 hasOpenAccess W2022868259 @default.
• W2022868259 hasPrimaryLocation W20228682591 @default.
• W2022868259 hasRelatedWork W1754479933 @default.
• W2022868259 hasRelatedWork W2022868259 @default.
• W2022868259 hasRelatedWork W2277416945 @default.
• W2022868259 hasRelatedWork W2349559277 @default.
• W2022868259 hasRelatedWork W2369999122 @default.
• W2022868259 hasRelatedWork W2376042985 @default.
• W2022868259 hasRelatedWork W2385730265 @default.
• W2022868259 hasRelatedWork W2416056649 @default.
• W2022868259 hasRelatedWork W3031161537 @default.
• W2022868259 hasRelatedWork W4221050677 @default.
• W2022868259 hasVolume "107" @default.
• W2022868259 isParatext "false" @default.
• W2022868259 isRetracted "false" @default.
• W2022868259 magId "2022868259" @default.
• W2022868259 workType "article" @default.